Valtecne (VLT) Q2 2026 TU earnings summary

Executive summary

• Consolidated revenues for the first half of 2026 reached €19.6 million, up 0.8% year-over-year.

• The Medical business line remains the primary market, accounting for 72.6% of total revenues.

• The Industrial business line showed strong growth, supporting overall production capacity utilization.

• An agreement with G Square was announced, aimed at accelerating future growth.

Financial highlights

• Medical business line revenues were €14.2 million, down 2.5% compared to the first half of 2025.

• Industrial business line revenues rose to €5.4 million, up 10.9% year-over-year.

• Total consolidated revenues increased slightly by 0.8% from €19.4 million to €19.6 million.

Outlook and guidance

• Management expresses confidence for the second half of the year, citing ongoing market opportunities.

• The company remains focused on the medical sector as its strategic priority.